Company Overview of BioMotiv, LLC
BioMotiv, LLC develops medicines for patients. It develops various types of therapeutics, such as small molecules, antibodies, proteins, cell therapies, and nucleotides. The company has a strategic partnership with Takeda Pharmaceutical Company Limited. BioMotiv, LLC was formerly known as BIOU, LLC. The company was founded in 2012 and is based in Cleveland, Ohio.
3605 Warrensville Center Road
Cleveland, OH 44122-2394
Founded in 2012
Key Executives for BioMotiv, LLC
Chief Executive Officer and Member of Board of Managers
Vice President of Business Development
Chairman of Scientific Advisory Board
Compensation as of Fiscal Year 2014.
BioMotiv, LLC Key Developments
Takeda Pharmaceutical Company Limited and BioMotiv, LLC Enter into Strategic Partnership
Sep 25 14
Takeda Pharmaceutical Company Limited and BioMotiv, LLC, announced that Takeda has made a strategic investment in BioMotiv and that they have formed a partnership that will leverage the strengths of both organizations to identify and develop pioneering medical innovations. The initial investment is $25 million over five years. This investment includes exclusive rights relating to programs sourced by BioMotiv specifically in the therapeutic areas of Immunology & Inflammation and Cardio-metabolic Diseases. Launched in 2012, The Harrington Project for Discovery & Development is a $250 million national initiative, comprising the not-for-profit Harrington Discovery Institute and BioMotiv, a for-profit therapeutic accelerator. The fundamental aim is to identify, fund and rapidly advance the development of medical breakthroughs from the most innovative and respected research institutions, as well as disease foundations, throughout the USA. This initiative is unique in targeting physician-scientist discoveries and providing bench-to-bedside clinical insights into disorders where the demand for truly innovative, new medicines is paramount.
BioMotiv to Develop BioAtla's TH22 Pathway-Directed Antibody for treatment of inflammatory bowel diseases and oncologic indications
Feb 20 14
BioAtla has licensed exclusive worldwide rights to BioMotiv to develop and commercialize its TH22 pathway-directed antibody compound for the treatment of inflammatory bowel diseases (IBD) and oncologic indications. In conjunction with the licensing deal, BioMotiv has established Kodosil Bio which will develop all compounds resulting from the license. BioAtla used its Comprehensive Integrated Antibody Optimization (CIAO!) platform for the identification, humanization and optimization of the monoclonal antibody. The platform selects candidates with natural protein folding and glycosylation, high protein expression and faster downstream process development characteristics, providing cost and time efficiencies all through the development process. Under the deal, BioAtla will provide its discovery and preclinical development processes for the licensed compounds, while Kodosil Bio will manage the development of the therapeutic antibody and will fund all discovery and development activities through clinical proof-of-concept.
BioMotive Presents at Life Sciences Summit 2013, Nov-21-2013 04:30 PM
Oct 3 13
BioMotive Presents at Life Sciences Summit 2013, Nov-21-2013 04:30 PM. Venue: Convene - Midtown East, 730 Third Avenue (Between East 45th and 46th Streets), 17th Floor, New York, NY 10017, United States. Speakers: Terry C. Vance, Chief Business Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 25, 2014